Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.04
CFN's Cash to Debt is ranked higher than
69% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. CFN: 1.04 )
CFN' s 10-Year Cash to Debt Range
Min: 0.56   Max: 1.49
Current: 1.04

0.56
1.49
Equity to Asset 0.60
CFN's Equity to Asset is ranked higher than
73% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.57 vs. CFN: 0.60 )
CFN' s 10-Year Equity to Asset Range
Min: 0.56   Max: 0.65
Current: 0.6

0.56
0.65
F-Score: 7
Z-Score: 3.24
M-Score: -2.44
WACC vs ROIC
2.09%
10.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.10
CFN's Operating margin (%) is ranked higher than
89% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.43 vs. CFN: 16.10 )
CFN' s 10-Year Operating margin (%) Range
Min: 12.35   Max: 17.44
Current: 16.1

12.35
17.44
Net-margin (%) 12.03
CFN's Net-margin (%) is ranked higher than
88% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. CFN: 12.03 )
CFN' s 10-Year Net-margin (%) Range
Min: 5.74   Max: 15.8
Current: 12.03

5.74
15.8
ROE (%) 9.10
CFN's ROE (%) is ranked higher than
77% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. CFN: 9.10 )
CFN' s 10-Year ROE (%) Range
Min: 3.82   Max: 13.35
Current: 9.1

3.82
13.35
ROA (%) 5.44
CFN's ROA (%) is ranked higher than
78% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. CFN: 5.44 )
CFN' s 10-Year ROA (%) Range
Min: 2.38   Max: 8.18
Current: 5.44

2.38
8.18
ROC (Joel Greenblatt) (%) 69.70
CFN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.59 vs. CFN: 69.70 )
CFN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 37.79   Max: 119.44
Current: 69.7

37.79
119.44
Revenue Growth (3Y)(%) 5.70
CFN's Revenue Growth (3Y)(%) is ranked higher than
77% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. CFN: 5.70 )
CFN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 5.7
Current: 5.7

0
5.7
EBITDA Growth (3Y)(%) 7.90
CFN's EBITDA Growth (3Y)(%) is ranked higher than
75% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. CFN: 7.90 )
CFN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 8.9
Current: 7.9

0
8.9
EPS Growth (3Y)(%) 14.10
CFN's EPS Growth (3Y)(%) is ranked higher than
81% of the 229 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. CFN: 14.10 )
CFN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 34.2
Current: 14.1

0
34.2
» CFN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CFN Guru Trades in Q1 2014

Ray Dalio 22,200 sh (New)
Diamond Hill Capital 213,940 sh (+117.33%)
Robert Olstein 222,000 sh (+1.37%)
First Pacific Advisors 4,568,100 sh (+0.36%)
Vanguard Health Care Fund 4,970,354 sh (unchged)
Steven Romick 4,325,000 sh (unchged)
Jeremy Grantham Sold Out
Pioneer Investments Sold Out
Jim Simons Sold Out
Steven Cohen 465,370 sh (-31.94%)
Joel Greenblatt 41,513 sh (-79.78%)
Paul Tudor Jones 18,292 sh (-92.34%)
» More
Q2 2014

CFN Guru Trades in Q2 2014

Larry Robbins 1,909,705 sh (New)
Jim Simons 125,000 sh (New)
Louis Moore Bacon 109,695 sh (New)
Paul Tudor Jones 361,300 sh (+1875.18%)
Vanguard Health Care Fund 5,661,354 sh (+13.90%)
Diamond Hill Capital 242,594 sh (+13.39%)
Steven Cohen 47,800 sh (unchged)
Ray Dalio Sold Out
Robert Olstein 208,000 sh (-6.31%)
First Pacific Advisors 3,801,500 sh (-16.78%)
Steven Romick 3,580,000 sh (-17.23%)
Joel Greenblatt 4,642 sh (-88.82%)
» More
Q3 2014

CFN Guru Trades in Q3 2014

Joel Greenblatt 817,023 sh (+17500.70%)
Jim Simons 394,500 sh (+215.60%)
Diamond Hill Capital 280,969 sh (+15.82%)
Vanguard Health Care Fund 5,661,354 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Larry Robbins Sold Out
Robert Olstein 195,000 sh (-6.25%)
First Pacific Advisors 3,299,800 sh (-13.20%)
Steven Romick 3,090,000 sh (-13.69%)
Paul Tudor Jones 9,100 sh (-97.48%)
» More
Q4 2014

CFN Guru Trades in Q4 2014

Jean-Marie Eveillard 120,000 sh (New)
Caxton Associates 30,087 sh (New)
Mario Gabelli 24,988 sh (New)
Vanguard Health Care Fund 5,661,354 sh (unchged)
First Pacific Advisors Sold Out
Steven Romick Sold Out
Robert Olstein Sold Out
Diamond Hill Capital 279,549 sh (-0.51%)
Paul Tudor Jones 8,300 sh (-8.79%)
Joel Greenblatt 290,264 sh (-64.47%)
Jim Simons 17,800 sh (-95.49%)
» More
» Details

Insider Trades

Latest Guru Trades with CFN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.50
CFN's P/E(ttm) is ranked higher than
86% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.80 vs. CFN: 25.50 )
CFN' s 10-Year P/E(ttm) Range
Min: 11.67   Max: 39.94
Current: 25.5

11.67
39.94
Forward P/E 22.03
CFN's Forward P/E is ranked higher than
79% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.73 vs. CFN: 22.03 )
N/A
PE(NRI) 25.50
CFN's PE(NRI) is ranked higher than
87% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 58.30 vs. CFN: 25.50 )
CFN' s 10-Year PE(NRI) Range
Min: 14.63   Max: 43.14
Current: 25.5

14.63
43.14
P/B 2.22
CFN's P/B is ranked higher than
78% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. CFN: 2.22 )
CFN' s 10-Year P/B Range
Min: 0.88   Max: 2.25
Current: 2.22

0.88
2.25
P/S 3.06
CFN's P/S is ranked higher than
56% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.32 vs. CFN: 3.06 )
CFN' s 10-Year P/S Range
Min: 1.3   Max: 3.16
Current: 3.06

1.3
3.16
PFCF 25.82
CFN's PFCF is ranked higher than
86% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 97.29 vs. CFN: 25.82 )
CFN' s 10-Year PFCF Range
Min: 15.26   Max: 139.05
Current: 25.82

15.26
139.05
POCF 21.02
CFN's POCF is ranked higher than
80% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.60 vs. CFN: 21.02 )
CFN' s 10-Year POCF Range
Min: 6.25   Max: 21.08
Current: 21.02

6.25
21.08
EV-to-EBIT 18.50
CFN's EV-to-EBIT is ranked higher than
88% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.87 vs. CFN: 18.50 )
CFN' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 19.4
Current: 18.5

8.3
19.4
PEG 3.40
CFN's PEG is ranked higher than
90% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. CFN: 3.40 )
CFN' s 10-Year PEG Range
Min: 0.94   Max: 3.48
Current: 3.4

0.94
3.48
Shiller P/E 37.21
CFN's Shiller P/E is ranked higher than
86% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. CFN: 37.21 )
CFN' s 10-Year Shiller P/E Range
Min: 23.41   Max: 37.21
Current: 37.21

23.41
37.21
Current Ratio 4.73
CFN's Current Ratio is ranked higher than
88% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. CFN: 4.73 )
CFN' s 10-Year Current Ratio Range
Min: 2.55   Max: 5.56
Current: 4.73

2.55
5.56
Quick Ratio 4.00
CFN's Quick Ratio is ranked higher than
88% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. CFN: 4.00 )
CFN' s 10-Year Quick Ratio Range
Min: 1.98   Max: 4.89
Current: 4

1.98
4.89
Days Inventory 82.24
CFN's Days Inventory is ranked higher than
87% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 133.28 vs. CFN: 82.24 )
CFN' s 10-Year Days Inventory Range
Min: 77.85   Max: 98.89
Current: 82.24

77.85
98.89
Days Sales Outstanding 46.24
CFN's Days Sales Outstanding is ranked higher than
90% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.74 vs. CFN: 46.24 )
CFN' s 10-Year Days Sales Outstanding Range
Min: 44.11   Max: 62.95
Current: 46.24

44.11
62.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.00
CFN's Price/Tangible Book is ranked higher than
58% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.30 vs. CFN: 10.00 )
CFN' s 10-Year Price/Tangible Book Range
Min: 3.95   Max: 9.89
Current: 10

3.95
9.89
Price/DCF (Projected) 1.80
CFN's Price/DCF (Projected) is ranked higher than
82% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. CFN: 1.80 )
CFN' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 1.81
Current: 1.8

1.13
1.81
Price/Median PS Value 1.70
CFN's Price/Median PS Value is ranked higher than
59% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. CFN: 1.70 )
CFN' s 10-Year Price/Median PS Value Range
Min: 0.78   Max: 1.69
Current: 1.7

0.78
1.69
Price/Peter Lynch Fair Value 2.90
CFN's Price/Peter Lynch Fair Value is ranked higher than
90% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. CFN: 2.90 )
CFN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.97   Max: 2.97
Current: 2.9

0.97
2.97
Price/Graham Number 3.30
CFN's Price/Graham Number is ranked higher than
82% of the 339 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. CFN: 3.30 )
CFN' s 10-Year Price/Graham Number Range
Min: 1.68   Max: 3.29
Current: 3.3

1.68
3.29
Earnings Yield (Greenblatt) 5.40
CFN's Earnings Yield (Greenblatt) is ranked higher than
87% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. CFN: 5.40 )
CFN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.2   Max: 12.1
Current: 5.4

5.2
12.1
Forward Rate of Return (Yacktman) 10.90
CFN's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. CFN: 10.90 )
CFN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.7   Max: 23.4
Current: 10.9

9.7
23.4

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 4,063 4,213 4,411
EPS($) 2.79 2.72 3.07
EPS without NRI($) 2.79 2.72 3.07

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:TCF.Germany,
CareFusion Corp a Delaware corporation was incorporated on January 14, 2009. It is a medical technology company. The Company offers a portfolio of products in the areas of medication management, infection prevention, operating room and procedural effectiveness, and respiratory care. Its primary product brands includes: Alaris intravenous (IV) infusion systems, Pyxis and Rowa automated medication dispensing and supply management systems, AVEA, Vela and LTV Series respiratory ventilators, ChloraPrep skin antiseptic products, MedMined data mining surveillance software and analytics, Vital Signs single-use consumables for respiratory care and anesthesiology, and Jaeger and SensorMedics cardiopulmonary diagnostic equipment. The Company operates in two business segments: Medical Systems and Procedural Solutions. In the Medical Systems segment, the Company develops, manufacture and market capital equipment and related supplies for medication management, which includes our infusion and medication dispensing technologies, supply management, as well as respiratory ventilation and diagnostic technologies. In the Procedural Solutions segment, the Company develops, manufacture and market single-use skin antiseptic and other patient-preparation products, specialty IV infusion valves, administration sets and accessories, IV catheters, IV drug preparation products, reusable surgical instruments, non-dedicated ventilator circuits and other disposables used for providing respiratory therapy, as well as single-use consumables for respiratory care and anesthesiology. The Company's competitors includes Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; Dräger; MAQUET, 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's operations are subject to the Federal Food, Drug and Cosmetic Act (FDC Act), as implemented and enforced by the United States Food and Drug Administration (FDA).
» More Articles for NYSE:CFN

Headlines

Articles On GuruFocus.com
Robert Olstein Comments on CareFusion Corp Mar 27 2015 
The Olstein Strategic Opportunities Fund’s Q4 2014 Letter to Shareholders Mar 27 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Fourth Quarter 2014 Crescent Fund Update Jan 26 2015 
Weekly 52-Week Highs Highlight: CFN, AAL, CUK, SHW, GGP Jan 05 2015 
The Gurus to Follow Based on Sector — Part 2 Dec 09 2014 
Dividend Aristocrats in Focus Part 18 of 54: Becton, Dickinson & Company Oct 14 2014 
Weekly 52-Week Highs Highlight: BDX, DUK, CFN, INFY Oct 12 2014 
No More a Simple Distributor Sep 07 2014 

More From Other Websites
CareFusion Demonstrates New Medication Safety Technologies At HIMSS15 Apr 14 2015
CareFusion to Host Medication Safety Presentations at HIMSS15 Apr 08 2015
Farallon Capital Adds a New Position in CareFusion Corporation Mar 26 2015
CAREFUSION CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of... Mar 17 2015
BECTON DICKINSON COMPLETES ACQUISITION OF CAREFUSION Mar 17 2015
Becton Dickinson Completes Acquisition Of CareFusion Mar 17 2015
European Commission Clears BD Acquisition Of CareFusion Mar 17 2015
European Regulator Oks Becton, Dickinson-CareFusion Deal - Analyst Blog Mar 16 2015
Celgene, Kinder Morgan and Actavis Set to Join the S&P 100; Several Constituent Changes Announced... Mar 13 2015
CAREFUSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 13 2015
European Commission Clears BD Acquisition Of CareFusion Mar 13 2015
European Commission Clears BD Acquisition Of CareFusion Mar 13 2015
Becton Dickinson wins EU approval for $12 bln CareFusion buy Mar 13 2015
MedMined® Surveillance Advisor Wins KLAS Category Leader Award Feb 27 2015
CareFusion Renews Infusion Pump Interoperability Certification Feb 25 2015
CAREFUSION CORP Financials Feb 13 2015
CareFusion to Distribute Breas Medical's Vivo Ventilators in US - Analyst Blog Feb 10 2015
CareFusion Signs Exclusive Distribution Agreement With Breas Medical Feb 09 2015
10-Q for CareFusion Corp. Feb 08 2015
CAREFUSION CORP Files SEC form 10-Q, Quarterly Report Feb 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK